Contraindicated (1)bortezomib will increase the degree or effect of mavacamten by affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Sturdy or reasonable CYP2C19 inhibitors may enhance mavacamten systemic exposure, leading to heart failure due to systolic dysfunction. Acute development or exacerbation of congestive heart failure and new onset of diminished left ventricular https://ciliobrevin-d11087.canariblogs.com/the-definitive-guide-to-verteporfin-42104137